Walleye Trading’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $5.18M | Sell |
11,600
-6,300
| -35% | -$2.94M | 0.01% | 1125 |
|
|
2025
Q4 | $8.12M | Sell |
17,900
-16,700
| -48% | -$7.2M | 0.01% | 1033 |
|
|
2025
Q3 | $13.6M | Buy |
34,600
+29,100
| +529% | +$12.2M | 0.02% | 748 |
|
|
2025
Q2 | $2.45M | Sell |
5,500
-28,000
| -84% | -$12.9M | ﹤0.01% | 1607 |
|
|
2025
Q1 | $16.2M | Sell |
33,500
-3,000
| -8% | -$1.4M | 0.04% | 519 |
|
|
2024
Q4 | $14.7M | Sell |
36,500
-44,800
| -55% | -$20.8M | 0.03% | 600 |
|
|
2024
Q3 | $37.8M | Buy |
81,300
+79,400
| +4,179% | +$38.1M | 0.08% | 258 |
|
|
2024
Q2 | $891K | Sell |
1,900
-22,000
| -92% | -$9.55M | ﹤0.01% | 2152 |
|
|
2024
Q1 | $9.99M | Sell |
23,900
-108,000
| -82% | -$45.7M | 0.02% | 722 |
|
|
2023
Q4 | $53.7M | Buy |
131,900
+60,000
| +83% | +$22.2M | 0.12% | 145 |
|
|
2023
Q3 | $25M | Buy |
71,900
+57,900
| +414% | +$20.2M | 0.07% | 296 |
|
|
2023
Q2 | $4.93M | Sell |
14,000
-5,100
| -27% | -$1.72M | 0.01% | 970 |
|
|
2023
Q1 | $6.02M | Buy |
19,100
+8,300
| +77% | +$2.49M | 0.01% | 910 |
|
|
2022
Q4 | $3.12M | Buy |
10,800
+5,200
| +93% | +$1.58M | 0.01% | 1377 |
|
|
2022
Q3 | $1.62M | Sell |
5,600
-18,000
| -76% | -$5.18M | ﹤0.01% | 1866 |
|
|
2022
Q2 | $6.65M | Sell |
23,600
-13,200
| -36% | -$3.53M | 0.02% | 858 |
|
|
2022
Q1 | $9.6M | Buy |
36,800
+14,100
| +62% | +$3.35M | 0.03% | 646 |
|
|
2021
Q4 | $4.99M | Sell |
22,700
-18,100
| -44% | -$3.52M | 0.02% | 978 |
|
|
2021
Q3 | $7.4M | Buy |
40,800
+30,500
| +296% | +$5.95M | 0.03% | 705 |
|
|
2021
Q2 | $2.08M | Sell |
10,300
-4,200
| -29% | -$879K | 0.01% | 1465 |
|
|
2021
Q1 | $3.12M | Sell |
14,500
-21,600
| -60% | -$4.74M | 0.01% | 983 |
|
|
2020
Q4 | $8.53M | Buy |
36,100
+20,400
| +130% | +$4.68M | 0.04% | 461 |
|
|
2020
Q3 | $4.27M | Sell |
15,700
-6,100
| -28% | -$1.68M | 0.02% | 654 |
|
|
2020
Q2 | $6.33M | Sell |
21,800
-14,500
| -40% | -$3.93M | 0.04% | 430 |
|
|
2020
Q1 | $8.64M | Buy |
36,300
+7,900
| +28% | +$1.81M | 0.07% | 224 |
|
|
2019
Q4 | $6.22M | Buy |
28,400
+18,300
| +181% | +$3.7M | 0.04% | 465 |
|
|
2019
Q3 | $1.71M | Buy |
10,100
+700
| +7% | +$124K | 0.01% | 1173 |
|
|
2019
Q2 | $1.72M | Sell |
9,400
-1,300
| -12% | -$227K | 0.01% | 1162 |
|
|
2019
Q1 | $1.97M | Sell |
10,700
-2,500
| -19% | -$462K | 0.02% | 1085 |
|
|
2018
Q4 | $2.19M | Buy |
13,200
+2,400
| +22% | +$416K | 0.02% | 1008 |
|
|
2018
Q3 | $2.08M | Buy |
10,800
+7,700
| +248% | +$1.37M | 0.01% | 1288 |
|
|
2018
Q2 | $527K | Buy |
+3,100
| New | +$481K | ﹤0.01% | 2792 |
|
|
2016
Q1 | – | Sell |
-300
| Closed | -$39K | – | 5888 |
|
|
2015
Q4 | $39K | Hold |
300
| – | – | ﹤0.01% | 4042 |
|
|
2015
Q3 | $31K | Sell |
300
-700
| -70% | -$89.9K | ﹤0.01% | 3824 |
|
|
2015
Q2 | $123K | Buy |
+1,000
| New | +$126K | ﹤0.01% | 2877 |
|
|
2014
Q4 | – | Sell |
-100
| Closed | -$11K | – | 4560 |
|
|
2014
Q3 | $11K | Hold |
100
| – | – | ﹤0.01% | 3759 |
|
|
2014
Q2 | $9 | Buy |
+100
| New | +$7.01K | ﹤0.01% | 3410 |
|
|
2014
Q1 | – | Sell |
-2,300
| Closed | -$170K | – | 3965 |
|
|
2013
Q4 | $170K | Sell |
2,300
-2,200
| -49% | -$153K | ﹤0.01% | 2248 |
|
|
2013
Q3 | $342K | Sell |
4,500
-5,300
| -54% | -$422K | ﹤0.01% | 1414 |
|
|
2013
Q2 | $784K | Buy |
+9,800
| New | +$722K | 0.01% | 1022 |
|
Other funds holding VRTX
VCM
VPM
Walleye Trading's VRTX Position: Q1 2026 in Review
Walleye Trading sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 13,339 shares — an estimated $6.22M sold.
Walleye Trading first reported a position in VRTX in Q2 2013 and held it in 38 quarters. The position peaked at $19.8M in Q3 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Walleye Trading reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Walleye Trading sold 13,339 Vertex Pharmaceuticals shares in Q1 2026, an estimated $6.22M.
- Walleye Trading first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 38 quarters.
- Walleye Trading's Vertex Pharmaceuticals position peaked at $19.8M in Q3 2024.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Walleye Trading's 13F filing for Q1 2026, filed 11 May 2026.